Announcement • May 19
Alpha Tau Medical Ltd., Annual General Meeting, Jun 23, 2026 Alpha Tau Medical Ltd., Annual General Meeting, Jun 23, 2026. Location: 5 kiryat hamada st., jerusalem 9777605., Israel Price Target Changed • May 13
Price target increased by 19% to US$10.75 Up from US$9.00, the current price target is an average from 4 analysts. New target price is 12% above last closing price of US$9.64. Stock is up 241% over the past year. The company posted a net loss per share of US$0.53 last year. Announcement • May 12
Alpha Tau Medical Ltd Announces Groundbreaking Interim Results from Its U.S. Alpha DaRT Recurrent Glioblastoma Trial Alpha Tau Medical Ltd. announced groundbreaking interim data from its U.S. trial of Alpha DaRT for patients with recurrent glioblastoma (GBM), also known as the REGAIN (Recurrent Glioblastoma Alpha-DaRT Intratumoral Therapy) trial. In accordance with the FDA’s request for an interim safety analysis, results were analyzed after three patients were treated in the trial, with one patient treated in each of December 2025, February 2026 and March 2026. No unanticipated associated SAEs have been observed as of the cutoff date of May 3, 2026, and only one associated grade 3 SAE was observed: seizure with temporary paralysis, which resolved with the administration of steroids. In addition, as measured via regular MRI scans and defined by Response Assessment in Neuro-Oncology (RANO) criteria, the first two patients demonstrated a continued complete response, signifying the total disappearance of all enhancing tumor lesions, and the third patient demonstrated stable disease with a 30% decrease in tumor dimension. As of the cutoff date, no patients have any local or distant recurrence, or any residual symptoms from the procedure, and the patient has recovered from the associated SAE. The first three patients were treated at The Ohio State University Comprehensive Cancer Center (OSUCCC) in Columbus, Ohio, by a multidisciplinary team using a novel delivery approach designed specifically by Alpha Tau for intracranial use. The REGAIN study is a prospective, open-label, single arm interventional study designed to evaluate the feasibility and safety of Alpha DaRT for the potential treatment of recurrent glioblastoma. The clinical trial is expected to enroll up to ten U.S. patients with recurrent GBM not amenable for surgical resection who have undergone a prior course of central nervous system radiation. The primary objective of the study is to evaluate the feasibility and safety of the treatment, following the Company’s promising results from pre-clinical studies. Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms dif fuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it. 
